Rockefeller University: Study Explains Why Checkpoint Inhibitors So Adept at Fighting Cancer May Also Leave Patients Vulnerable to Infections
November 27, 2024
November 27, 2024
NEW YORK, Nov. 27 (TNSres) -- Rockefeller University issued the following news:
People with cancer now have a multitude of treatment options beyond chemotherapy and radiation. One such advanced approach, called immune checkpoint inhibitor therapy, enables immune cells called T cells to attack tumors and cancer cells far more effectively. But 20% of patients who receive this therapy develop a dangerous side effect: an increased chance of microbial infection. Why has remained poorly u . . .
People with cancer now have a multitude of treatment options beyond chemotherapy and radiation. One such advanced approach, called immune checkpoint inhibitor therapy, enables immune cells called T cells to attack tumors and cancer cells far more effectively. But 20% of patients who receive this therapy develop a dangerous side effect: an increased chance of microbial infection. Why has remained poorly u . . .